During HER2+ breast cancer treatment, ADCC is induced when the CD16 or FcƴRIII on the NK cells binds to the Fc domain of trastuzumab that has already recognized the HER2 molecule on the cancer cell. Here, FCGR3A is linked to breast carcinoma.